Aggressive treatment with ranibizumab during year 3 may be more effective for diabetic macular edema (DME) than less-intensive treatment, according to 3-year outcomes from an ongoing randomized clinical trial published online October 8 in the Archives of Ophthalmology. Ranibizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF), which promotes angiogenesis. The purpose of this prospective, interventional, multicenter follow-up study was to evaluate the benefit of increased follow-up and treatment with ranibizumab between months 24 and 36 in the Ranibizumab for Edema of the Macula in Diabetes (READ-2) Study.To see more details visit, www.medscape.com
